Recently, zenocutuzumab was approved for the treatment of adult patients with advanced unresectable or metastatic non-small cell lung or pancreatic cancer who are positive for NRG1 fusion and who have experienced disease progression despite other treatments. The gene discussed is NRG1; the disease is familial pancreatic carcinoma.